LivingGLP1
Study S000473

Effects of Lixisenatide on Gastric Emptying, Glycaemia and 'Postprandial' Blood Pressure in Type 2 Diabetes and Healthy Subjects.

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT02308254
Acronym
Lixi
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE1; PHASE2
Masking
DOUBLE
Status
UNKNOWN
Enrollment
30
Start
2013-11
Primary completion
2016-04
Lead sponsor
Royal Adelaide Hospital
Conditions
Diabetes Mellitus; Gastroparesis
Interventions
DRUG:Lixisenatide; DRUG:Placebo
Results posted
FALSE

Registered primary outcomes

  • Blood Pressure [4.5 hours per study]

Linked records (10)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0015276Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying.
Marathe CS, Diabetes therapy : research, treatment and education of diabetes and related disorders
2022Randomized trialPMID 35460043DOIcites ClinicalTrials.gov:NCT02308254; registry reference DERIVED:35460043
R0052837Acute effects of lixisenatide on intragastric meal distribution: impact on energy intake
Ryan J. Jalleh, HAL (Le Centre pour la Communication Scientifique Directe)
2019Other trialcites ClinicalTrials.gov:NCT02308254
R0016316Mechanisms and clinical efficacy of lixisenatide for the management of type 2 diabetes.
Horowitz M, Advances in therapy
2013Other trialPMID 23423907DOIregistry reference BACKGROUND:23423907
R0025751Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal-P).
Pinget M, Diabetes, obesity & metabolism
2013Randomized trialPMID 23627775DOIregistry reference BACKGROUND:23627775
R0022843Efficacy and safety of the once-daily GLP-1 receptor agonist lixisenatide in monotherapy: a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono).
Fonseca VA, Diabetes care
2012Randomized trialPMID 22432104DOIregistry reference BACKGROUND:22432104
R0027814The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.
Stevens JE, Alimentary pharmacology & therapeutics
2012Randomized trialPMID 22738299DOIregistry reference BACKGROUND:22738299
R0019892Lixisenatide for type 2 diabetes mellitus.
Christensen M, Expert opinion on investigational drugs
2011Narrative reviewPMID 21391833DOIregistry reference BACKGROUND:21391833
R0020147Efficacy and safety of incretin based therapies: clinical trial data.
White J, Journal of the American Pharmacists Association : JAPhA
2009Randomized trialPMID 19801363DOIregistry reference BACKGROUND:19801363
R0028043Effects of intravenous glucagon-like peptide-1 on gastric emptying and intragastric distribution in healthy subjects: relationships with postprandial glycemic and insulinemic responses.
Little TJ, The Journal of clinical endocrinology and metabolism
2006Nonrandomized studyPMID 16492694DOIregistry reference BACKGROUND:16492694
R0025779Interactions of exendin-(9-39) with the effects of glucagon-like peptide-1-(7-36) amide and of exendin-4 on arterial blood pressure and heart rate in rats.
Barragán JM, Regulatory peptides
1996PreclinicalPMID 8952007DOIregistry reference BACKGROUND:8952007